Lupus activation with cerebritis following pegylated interferon in a hemodialysis patient

Nature Reviews Nephrology

Volumn 5, Issue 10, 2009, Pages 599-603

  Agarwal, Sanjay Kumar ^a   Lal, Charanjeet ^a   Zaidi, Sabahat Husain ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; DNA ANTIBODY; ELECTROLYTE; INFUSION FLUID; METHYLPREDNISOLONE; OXYGEN; PEGINTERFERON; PHENYTOIN; PREDNISOLONE;

ADULT; ARTICLE; BLOOD CELL COUNT; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROLYTE BLOOD LEVEL; ENCEPHALITIS; FEMALE; HEMODIALYSIS; HEPATITIS C; HUMAN; KIDNEY FAILURE; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY;

ADOLESCENT; ANTIVIRAL AGENTS; ENCEPHALITIS; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LUPUS ERYTHEMATOSUS, SYSTEMIC; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; YOUNG ADULT;

EID: 70349632126     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.137     Document Type: Article

References (18)

1. Ishak, K. et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22, 696-699 (1995).
2. Wilson, L. e., Widman, d., dikman, s. H. & Gorevic, P. d. autoimmune disease complicating antiviral therapy for hepatitis c virus infection. Semin. Arthritis Rheum. 32, 163-173 (2002).
3. Ho, V., McLean, a. & terry, s. severe systemic lupus erythematosus induced by antiviral treatment for hepatitis c. J. Clin. Rheumatol. 14, 166-168 (2008).
4. Niewold, t. B. & swedler, W. I. systemic lupus erythematosus arising during interferon-a therapy for cryoglobulinemic vasculitis associated with hepatitis c. Clin. Rheumatol. 24, 178-181 (2005).
5. Goyal, H. K. et al. Interferon-induced lupus nephritis in a patient with chronic myeloid leukemia. Leuk. Lymphoma 46, 481-482 (2005).
6. Pouthier, d., theissen, F. & Humbel, R. L. Lupus syndrome, hypothyroidism and bullous skin lesions after interferon-a therapy for hepatitis c in a haemodialysis patient. Nephrol. Dial. Transpl. 17, 174 (2002).
7. Gladman, d. d. & urowitz, M. B. systemic lupus erythematosus: clinical and laboratory features. In Primer on the Rheumatic Diseases 11th edn (eds Klippel, J. H. et al.) 251-257 (arthritis Foundation, atlanta, 1997).
8. chow, K. M. et al. Nonconvulsive status epilepticus in peritoneal dialysis patients. Am. J. Kidney Dis. 38, 400-405 (2001).
9. Beccari, M. seizures in dialysis patients treated with recombinant erythropoietin. Review of the literature and guidelines for prevention. Int. J. Artif. Organs 17, 5-13 (1994).
10. cheigh, J. s. et al. systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am. J. Kidney Dis. 16, 189-195 (1990).
11. Okano, K. et al. analysis of lupus activity in endstage renal disease treated by hemodialysis. Intern. Med. 40, 598-602 (2001).
12. szeto, c. c., Li, P. K., Wong, t. y., Leung, c. B. & Lui, s. F. Factors associated with active systemic lupus erythematosus after end-stage renal disease. J. Rheumatol. 25, 1520-1525 (1998).
13. Pellicano, R. et al. autoimmune manifestations during interferon therapy in patients with chronic hepatitis c: the hepatologist's view. Minerva Gastroenterol. Dietol. 51, 55-61 (2005).
14. RxList: the Internet drug Index. Pegasys [online], http://www.rxlist.com/ pegasys-drug.htm (2009).
15. selmi, c. et al. Interferon á and its contribution to autoimmunity. Curr. Opin. Investig. Drugs 7, 451-456 (2006).
16. santiago-Raber, M. L. et al. type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197, 777-788 (2003).
17. akhan, s. c., Kalender, B. & Ruzgar, M. the response to pegylated interferon á2a in haemodialysis patients with hepatitis c virus infection. Infection 36, 341-344 (2008).
18. Zimmermann, t. et al. efficacy of an escalating dose regimen of pegylated interferon á2a plus ribavirin in the early phase of HcV reinfection after liver transplantation. Transpl. Int. 20, 583-590 (2007).